Optimizing immunization schedules in endemic cholera regions: cost-effectiveness assessment of vaccination strategies for cholera control in Bangladesh.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
15 10 2021
Historique:
received: 11 05 2021
revised: 06 09 2021
accepted: 16 09 2021
pubmed: 29 9 2021
medline: 26 10 2021
entrez: 28 9 2021
Statut: ppublish

Résumé

This study is to examine the cost-effectiveness of deployment strategies of oral cholera vaccines (OCVs) in controlling cholera in Bangladesh. We developed a dynamic compartment model to simulate costs and health outcomes for 12 years for four OCVs deployment scenarios: (1) vaccination of children aged one and above with two doses of OCVs, (2) vaccination of population aged 5 and above with a single dose of OCVs, (3) vaccination of children aged 1-4 with two doses of OCVs; and (4) combined strategy of (2) and (3). We obtained all parameters from the literature and performed a cost-effectiveness analysis from both health systems and societal perspectives, in comparison with the base scenario of no vaccination.The incremental cost-effectiveness ratios (ICERs) for the four strategies from the societal perspective were $2,236, $2,250, $1,109, and $2,112 per DALY averted, respectively, with herd immunity being considered. Without herd immunity, the ICERs increased substantially for all four scenarios except for the scenario that vaccinates children aged 1-4 only. The major determinants of ICERs were the case fatality rate and the incidence of cholera, as well as the efficacy of OCVs. The projection period and frequency of administering OCVs would also affect the cost-effectiveness of OCVs. With the cut-off of 1.5 times gross domestic product per capita, the four OCVs deployment strategies are cost-effective. The combined strategy is more efficient than the strategy of vaccinating the population aged one and above with two doses of OCVs and could be considered in the resource-limited settings.

Identifiants

pubmed: 34579976
pii: S0264-410X(21)01235-4
doi: 10.1016/j.vaccine.2021.09.044
pii:
doi:

Substances chimiques

Cholera Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6356-6363

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Wu Zeng (W)

Department of International Health, School of Nursing and Health Studies, Georgetown University, Washington, DC, USA. Electronic address: wz192@georgetown.edu.

Yujie Cui (Y)

Shanghai Jiao Tong University School of Medicine, Shanghai, China; China Hospital Management Institute, Shanghai Jiao Tong University, Shanghai, China. Electronic address: cuiyujie@sjtu.edu.cn.

Eva Jarawan (E)

Department of International Health, School of Nursing and Health Studies, Georgetown University, Washington, DC, USA. Electronic address: ej206@georgetown.edu.

Carlos Avila (C)

Palladium Group, London, UK. Electronic address: Carlos.Avila@thepalladiumgroup.com.

Guohong Li (G)

Shanghai Jiao Tong University School of Medicine, Shanghai, China; China Hospital Management Institute, Shanghai Jiao Tong University, Shanghai, China. Electronic address: guohongli@sjtu.edu.cn.

Vincent Turbat (V)

Department of International Health, School of Nursing and Health Studies, Georgetown University, Washington, DC, USA. Electronic address: vmt24@georgetown.edu.

Jennifer Bouey (J)

Department of International Health, School of Nursing and Health Studies, Georgetown University, Washington, DC, USA. Electronic address: zh34@georgetown.edu.

Marwa Farag (M)

School of Public Health, University of Saskatchewan, Saskatoon, SK, Canada School of Public Administration and Development Economics, Doha Institute for Graduate Studies, Doha, Qatar. Electronic address: marwa.farag@usask.ca.

Ronald Mutasa (R)

The World Bank Group, Washington DC, USA. Electronic address: rmutasa@worldbank.org.

Haksoon Ahn (H)

School of Social Work, University of Maryland, Baltimore, MD, USA. Electronic address: Hahn@ssw.umaryland.edu.

Daxin Sun (D)

College of Transportation and Civil Engineering, Fujian Agriculture and Forestry University, Fuzhou, China. Electronic address: ffcsdx@126.com.

Jie Shen (J)

Shanghai Jiao Tong University School of Medicine, Shanghai, China; China Hospital Management Institute, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shenjie@shsmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH